Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Ann Clin Transl Neurol
; 11(5): 1338-1346, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38572524
ABSTRACT
OBJECTIVE:
Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti-acetylcholine receptor-positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent analyses. The purpose of the present study was to evaluate the clinical significance of eculizumab and switching to ravulizumab for refractory AChR+ gMG patients in the real-world experience.METHODS:
Among the database of Japan MG registry survey 2021, we studied AChR+ gMG patients who received eculizumab. We also evaluated these patients who switched from eculizumab to ravulizumab. Responder was defined as an improvement of at least 3 points in MG-ADL. We performed a questionnaire of preference between eculizumab and ravulizumab.RESULTS:
Among 1,106 patients with AChR+ gMG, 36 patients (3%) received eculizumab (female 78%, mean age 56.0 years). Eculizumab was preferentially used in severe and refractory MG patients. The duration of eculizumab treatment was 35 months on average. MG-ADL improved from 9.4 ± 4.9 to 5.9 ± 5.1, and 25 (70%) of the 36 gMG patients were responders. Postintervention status was markedly improved after the eculizumab treatment. Of 13 patients who did not continue eculizumab, 6 showed insufficiencies. Early onset MG was most effective. However, 15 patients switching from eculizumab to ravulizumab kept favorable response and tolerability. Questionnaire surveys showed preference for ravulizumab over eculizumab.INTERPRETATION:
Eculizumab and switching to ravulizumab showed to be effective for refractory AChR+ gMG patients in clinical settings.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inactivadores del Complemento
/
Anticuerpos Monoclonales Humanizados
/
Miastenia Gravis
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Asia
Idioma:
En
Revista:
Ann Clin Transl Neurol
/
Ann. clin. transl. neurol
/
Annals of clinical and translational neurology
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón